A centrally active drug that modulates AMPA receptor gated currents

doi:10.1016/0006-8993(94)90669-6

Brain Research

Volume 638, Issues 1–2, 28 February 1994, Pages 343-346

https://doi.org/10.1016/0006-8993(94)90669-6 Get rights and content

Abstract

Systemic administration of the drug 1-(1,3-benzodioxol-5-ylcarbonyl)-piperidine (1-BCP) has been reported to enhance monosynaptic response in the hippocampus in vivo and to improved spatial and olfactory memory in rats. The drug's mechanism of action was investigated in the present study using membrane patches fromm cultured hippocampal slices. The decay time of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor mediated inward currents was greatly increased by 1-CBP in a concentration dependent and reversible fashion; peak current was also enhanced but to a lesser degree. In vitro slice experiments indicated that the drug has a parallel effects on the field of EPSP. It is concluded that 1-BCP is a centrally active modulator of the AMPA receptor.

References (5)

StoppiniL. et al.
A simple method for organotypic cultures oissue
J. Neurosci. Meth.
(1991)
ItoI. et al.
Allosteric potentiation of quisqualate receptors by a nootropic drug anuractctam
J. Physiol.
(1990)

There are more references available in the full text version of this article.

Cited by (115)

Drug Discovery for Targeted Pharmacotherapy of Fragile X Syndrome
2017, Fragile X Syndrome: From Genetics to Targeted Treatment
Fragile X syndrome (FXS) is the most common monogenic form of inherited mental retardation caused by a CGG trinucleotide repeat expansion and transcriptional shutdown of the FMR1 gene. FXS patients present with a complex and often severe neuropsychiatric phenotype with considerable heterogeneity caused in part by varying trinucleotide repeat sizes, as well as somatic and X-chromosomal mosaicism. Early availability of Fmr1 knockout mice and other disease models have been invaluable for understanding the molecular pathophysiology of FXS and for testing potential pharmacological interventions. Recent clinical trials with a GABA_B agonist and with mGlu5 inhibitors showed no significant therapeutic benefits in FXS patients in spite of compelling preclinical data suggesting profound and comprehensive therapeutic effects for both modalities. These discrepancies indicate that improving the translation from preclinical results to clinical trial outcomes requires a careful examination of the preclinical disease models, preclinical and clinical outcome measures, as well as clinical trial design.
The NMDA receptor as a target for cognitive enhancement
2013, Neuropharmacology
NMDA receptors (NMDARs) play an important role in neural plasticity including long-term potentiation and long-term depression, which are likely to explain their importance for learning and memory. Cognitive decline is a major problem facing an ageing human population, so much so that its reversal has become an important goal for scientific research and pharmaceutical development. Enhancement of NMDAR function is a core strategy toward this goal. In this review we indicate some of the major ways of potentiating NMDAR function by both direct and indirect modulation. There is good evidence that both positive and negative modulation can enhance function suggesting that a subtle approach correcting imbalances in particular clinical situations will be required. Excessive activation and the resultant deleterious effects will need to be carefully avoided. Finally we describe some novel positive allosteric modulators of NMDARs, with some subunit selectivity, and show initial evidence of their ability to affect NMDAR mediated events.
This article is part of a Special Issue entitled ‘Cognitive Enhancers’.
Essential role of protein kinase C in morphine-induced rewarding memory
2012, Neuropharmacology
Protein kinase C (PKC) is involved in intra-cellular signal transduction in various physiological and pathological processes including substance abuse. In the present study, the role of PKC in morphine-induced rewarding memory was investigated using the conditioned place preference (CPP) model. We found a significant translocation of PKCs from cytosol to membrane component in nucleus accumbens (NAc) of morphine-conditioned rats in a dose-dependent manner. The translocation was reduced gradually with the maintenance of morphine-induced CPP. Specifically, the protein level of PKCγ in membrane of the NAc was increased in morphine CPP rats, and decreased during the attenuation of morphine-induced CPP, while the protein level of PKCγ in cytosol of the NAc showed an opposite change. Furthermore, the PKC translocation inhibitor γV5-3 impaired the morphine-induced CPP when microinjected into the NAc. These findings indicated that PKC, especially the γ isoform, is essential for the acquisition and maintenance of morphine-associated reward memory.
This article is part of a Special Issue entitled ‘Post-Traumatic Stress Disorder’.
The AMPA receptor positive allosteric modulator, S18986, is neuroprotective against neonatal excitotoxic and inflammatory brain damage through BDNF synthesis
2009, Neuropharmacology
Brain lesions induced in newborn mice by the glutamatergic agonists ibotenate (acting on NMDA and metabotropic receptors) or S-willardiine (acting on AMPA-kainate receptors) mimic some aspects of periventricular white matter lesions and neocortical grey matter damage observed in human neonates at risk for developing cerebral palsy. The neonatal mouse brain can be sensitized to excitotoxic damage by IL-1β exposure similar to that observed in the human situation. Positive modulators of AMPA receptors have received increasing attention as potential neuroprotective agents in a number of neurodegenerative disorders of the adult. However whether they can also act as a neuroprotectant in neonatal brain damage has yet to be defined. Therefore the present study uses a well-defined rodent model of neonatal excitotoxic brain lesions to assess the neuroprotective effects of S18986, a positive allosteric modulator of AMPA receptors, as well as its mechanisms of action. In this model, S18986 provided a dose-dependent and long-lasting protection of developing white matter and cortical grey matter against an excitotoxic insult and also when this was combined with a sensitizing inflammatory insult. Neuroprotective effects of S18986 in cortical grey matter involved decreased necrotic and apoptotic cell death. S18986-induced neuroprotection against NMDA receptor-mediated brain lesions was blocked by inhibitors of ERK and PI3 kinase–Akt pathways. S18986 effects were abolished by a neutralizing anti-BDNF antibody and real time PCR confirmed the stimulation by S18986 of BDNF production in the neonatal brain. The present study provides strong experimental support for the role of S18986 as a candidate molecule for therapy in cases of excitotoxic perinatal brain lesions and identifies BDNF as a key mediator of this S18986-mediated neuroprotection.
A novel class of allosteric modulators of AMPA/Kainate receptors
2009, Bioorganic and Medicinal Chemistry Letters
Enantiomerization and hydrolysis of (±)-7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide by stopped-flow multidimensional high-performance liquid chromatography
2008, Journal of Chromatography A
A novel stopped-flow multidimensional HPLC (sf-MD-HPLC) procedure has been developed to investigate simultaneously the effect of the pH on the enantiostability and hydrolysis of (±)-7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide [(±)IDRA21]. It was possible to determinate the rate constants and free energy barriers of enantiomerization and hydrolysis rate constants of (±)IDRA21, by using two chiral stationary phases (CSPs) and one achiral C18 column. A classical batchwise kinetic method was used to calculate rate constants of hydrolysis at the same temperature and in the same buffers used in sf-MD-HPLC. The good agreement of the results obtained validate the sf-MD-HPLC procedure. Furthermore, hydrolysis rate constants of (±)IDRA21 were calculated in a series of buffers over a pH range of 1.20–10.60 at 37 °C in order to evaluate the influence of the pH on hydrolysis.

View all citing articles on Scopus

: This research was supported by a Grant from the AFOSR.

¹: The authors wish to express their sincere thanks to Dr. C.-M. Tang for his technical advice concerning the construction of the fast-switching system and for providing various components for the setup. The author thank Jackie Porter and Marla Lay for their secretarial assistance.

View full text

A centrally active drug that modulates AMPA receptor gated currents

Abstract

J. Neurosci. Meth.

Allosteric potentiation of quisqualate receptors by a nootropic drug anuractctam

J. Physiol.